January 31, 2025 08:38 AM EST

Celltrion looks to buy US facilities to sidestep potential Trump tariffs

Anna Brown

News Reporter

South Korean biopharma contract manufacturer Celltrion is considering acquiring US manufacturing sites to mitigate President Donald Trump’s potential tariffs on foreign-made pharmaceuticals.

Trump is …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Celltrion looks to buy US facilities to sidestep potential Trump tariffs

Anna Brown

News Reporter

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Novartis claims best earnings in years, validating shift to pure-play strategy

Roche separates CFO, informatics posts; Lilly execs land at Kailera, Neurocrine

Vertex's non-opioid pain drug is approved by FDA, bringing first of new class to market

Friday IPO doubleheader from Maze and Metsera brings life to biotech debuts

AbbVie raises Skyrizi and Rinvoq estimates, predicts $31B in 2027 sales

Why the premier recruitment agency in the world is giving up recruiting, and sponsors should, too

Cell­tri­on looks to buy US fa­cil­i­ties to side­step po­ten­tial Trump tar­iffs

News Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Celltrion looks to buy US facilities to sidestep potential Trump tariffs